Senti Biosciences Inc (SNTI)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.33-2.49%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SNTI
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue advancing SENTI-202 through pivotal Phase clinical trials with regulatory engagement and manufacturing improvements.
Stated as a priority in 2 of last 2 quarters. Management highlighted positive FDA feedback on SENTI-202 pivotal trial design and finalized manufacturing strategy using Donor X attribute. Revenue grew slightly from $16,000 in 2026-Q1 to $17,000 in 2026-Q2. The trajectory shows delivering progress consistent with management's stated focus.
“SENTI-202 granted RMAT designation and continues durable MRD-negative responses in Phase 1 trial.”
“Positive FDA feedback supports single-arm pivotal trial for SENTI-202 in R/R AML.”
Pursue mergers, acquisitions, and strategic transactions to unlock value and focus on core technology platforms.
Stated as a priority in 2 of last 2 quarters. Management executed a $40 million convertible notes financing agreement in 2026-Q1 and announced a strategic spin-off transaction in 2026-Q2 to unlock value for the Gene-Circuit-enabled pipeline. These actions demonstrate delivering on the M&A and strategic transaction focus.
“Announced strategic transaction to spin off Gene-Circuit-enabled pipeline including SENTI-202.”
“Entered securities purchase agreement with Celadon Partners for up to $40 million financing.”
Continue operational streamlining and restructuring to reduce net loss and cash burn.
Stated as a priority in 2 of last 2 quarters. Management reported operational streamlining and lease amendments reducing expenses. Net loss increased from -$4.2M in 2026-Q1 to -$12.75M in 2026-Q2, reflecting higher expenses or other factors, while cash burn was -$7.48M in 2026-Q1. The trajectory shows limited progress on reducing net loss but ongoing focus on cost discipline.
“Completed amendments to leases and subleases reducing future obligations and operating expenses.”
“Continued operational streamlining contributed to substantially reduced quarterly net loss and cash burn.”
Manage capital allocation prudently including financing agreements and milestone-based contingent value rights.
Stated as a priority in 2 of last 2 quarters. Management executed a $40 million convertible notes financing in 2026-Q1 and structured contingent value rights up to $60 million in 2026-Q2 tied to SENTI-202 milestones. These actions show delivering on capital allocation and financing strategy.
“Announced contingent value rights up to $60 million for SENTI-202 development and commercialization milestones.”
“Entered securities purchase agreement for up to $40 million in convertible notes.”
Pursue mergers and acquisitions to streamline operations and enhance business pipeline.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Over the trailing year it converted 0.40x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
24 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.